Evidence map›Paper›PMID 36798219›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Functional investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment.

Kashi Raj Bhattarai, Robert J Mobley, Kelly R Barnett, Daniel C Ferguson, Baranda S Hansen, Jonathan D Diedrich, Brennan P Bergeron, Wenjian Yang, Kristine R Crews, Christopher S Manring and 14 more

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 6 institutions in 3 countries.

Kashi Raj BhattaraiHematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN.
Robert J MobleyHematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN.
Kelly R BarnettHematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN.
Daniel C FergusonHematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN.
Baranda S HansenCenter for Advanced Genome Engineering, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Jonathan D DiedrichHematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN.
Brennan P BergeronHematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN.
Wenjian YangHematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN.
Kristine R CrewsHematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN.
Christopher S ManringAlliance Hematologic Malignancy Biorepository; Clara D. Bloomfield Center for Leukemia Outcomes Research, Columbus, OH 43210, USA.
Elias JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Elisabeth PaiettaAlbert Einstein College of Medicine, New York, NY.
Mark R LitzowDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Steven M KornblauDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Wendy StockComprehensive Cancer Center, University of Chicago Medicine, Chicago, IL.
Hiroto InabaHematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN.
Sima JehaHematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN.
Ching-Hon PuiHematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN.
Cheng ChengDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN.
Shondra M Pruett-MillerCenter for Advanced Genome Engineering, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Mary V RellingHematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN.
Jun J YangHematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN.
William E EvansHematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN.
Daniel SavicHematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN.
St. Jude Children's Research Hospital · USThe University of Texas MD Anderson Cancer Center · USAlbert Einstein College of Medicine · USMayo Clinic in Arizona · USTaiwan Comprehensive University System · TWUniversity of Chicago · US

Funding

Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6M
Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Shondra Michelle Miller · 1985 to 2026
$166.9M
ECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · 2015 to 2026
$41.1M
CPML - Project 3: Genome-wide Studies of Adverse EffectsP50GM115279 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI LOH, MIGNON LEE-CHEUN, RELLING, MARY V · 2015 to 2019
$15.1M
Montefiore Academic Community NCORP ProgramUG1CA189859 · NCI · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI Balazs Halmos, Della Makower · 2014 to 2026
$10.8M
NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1 (funded extension)UG1CA232760 · NCI · MAYO CLINIC ROCHESTER · PI Judy Caroline Boughey, Aaron Scott Mansfield · 2019 to 2026
$8.5M
Characterizing noncoding GWAS variants in acute lymphoblastic leukemia treatment outcomeR01CA234490 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI SAVIC, DANIEL · 2019 to 2023
$2.4M
NCI NIH HHS P30 CA021765NCI NIH HHS R01 CA234490NCI NIH HHS U10 CA180820NCI NIH HHS U24 CA196172NCI NIH HHS UG1 CA189859NCI NIH HHS UG1 CA232760NIGMS NIH HHS P50 GM115279
6 · The paper itself

Abstract

Although acute lymphoblastic leukemia (ALL) is the most common childhood cancer, there is limited understanding of the contribution of inherited genetic variation on inter-individual differences in chemotherapy response. Defining genetic factors impacting therapy failure can help better predict response and identify drug resistance mechanisms. We therefore mapped inherited noncoding variants associated with chemotherapeutic drug resistance and/or treatment outcome to ALL

Identifiers

PMID36798219
PMCPMC9934807
OpenAlexW4320033868

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.